How We Use Corticosteroids in Immune Thrombocytopenia

ABSTRACT Introduction Corticosteroids remain an important first‐line treatment for immune thrombocytopenia (ITP), but their benefits are accompanied by substantial toxicities across various body systems. Their use should therefore be individualised and time‐limited. Methods We synthesise current guidance and published evidence concerning the selection of patients for corticosteroids treatment, choice of regimen, prevention and monitoring of treatment‐related toxicity, recognition of response and non‐response, and structured tapering and discontinuation in adults with ITP. Results Corticosteroids should be avoided when observation is clinically appropriate and, when prescribed, should have a pre‐defined indication, haemostatic control target, expected time to response and stopping date. Accepted first‐line regimens include prednisolone at 1–2 mg/kg/day, generally capped at 60–80 mg daily, or high‐dose dexamethasone at 40 mg daily for 4 days. A platelet count exceeding 50 × 10 9 /L within 5–7 days generally identifies an early responder, although a lower count may be adequate when bleeding has resolved and haemostatic safety has been achieved. Responders receiving prednisolone should proceed to dose reduction and complete discontinuation within approximately 6–8 weeks. Patients without an adequate early response should have prednisolone tapered over approximately 2 weeks and with prompt consideration of an alternative or steroid‐sparing treatment rather than prolonged dose escalation. Treatment extending beyond 3 weeks, particularly at doses exceeding 5 mg/day of prednisolone equivalent, may confer a risk of hypothalamic‐pituitary‐adrenal axis suppression and require a more structured taper. Conclusions Clinicians must balance the therapeutic goals of corticosteroids against the risk of toxicities from their use. The objective of corticosteroid therapy in ITP is to achieve haemostatic safety rather than to elevate or normalise the platelet count. Trial Registration The authors have confirmed clinical trial registration is not needed for this submission

Authors

Institutions

Publication Details

Journal
eJHaem
Published
2026-11-17
DOI
https://doi.org/10.1002/jha2.70460
Primary Topic
Platelet Disorders and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

How We Use Corticosteroids in Immune Thrombocytopenia

Mervyn Morgan, Drew Provan, Jecko V. Thachil, Gerard Gurumurthy
eJHaem
Platelet Disorders and Treatments
article

How We Use Corticosteroids in Immune Thrombocytopenia

Mervyn Morgan, Drew Provan, Jecko V. Thachil, Gerard Gurumurthy
article en

Abstract

ABSTRACT Introduction Corticosteroids remain an important first‐line treatment for immune thrombocytopenia (ITP), but their benefits are accompanied by substantial toxicities across various body systems. Their use should therefore be individualised and time‐limited. Methods We synthesise current guidance and published evidence concerning the selection of patients for corticosteroids treatment, choice of regimen, prevention and monitoring of treatment‐related toxicity, recognition of response and non‐response, and structured tapering and discontinuation in adults with ITP. Results Corticosteroids should be avoided when observation is clinically appropriate and, when prescribed, should have a pre‐defined indication, haemostatic control target, expected time to response and stopping date. Accepted first‐line regimens include prednisolone at 1–2 mg/kg/day, generally capped at 60–80 mg daily, or high‐dose dexamethasone at 40 mg daily for 4 days. A platelet count exceeding 50 × 10 9 /L within 5–7 days generally identifies an early responder, although a lower count may be adequate when bleeding has resolved and haemostatic safety has been achieved. Responders receiving prednisolone should proceed to dose reduction and complete discontinuation within approximately 6–8 weeks. Patients without an adequate early response should have prednisolone tapered over approximately 2 weeks and with prompt consideration of an alternative or steroid‐sparing treatment rather than prolonged dose escalation. Treatment extending beyond 3 weeks, particularly at doses exceeding 5 mg/day of prednisolone equivalent, may confer a risk of hypothalamic‐pituitary‐adrenal axis suppression and require a more structured taper. Conclusions Clinicians must balance the therapeutic goals of corticosteroids against the risk of toxicities from their use. The objective of corticosteroid therapy in ITP is to achieve haemostatic safety rather than to elevate or normalise the platelet count. Trial Registration The authors have confirmed clinical trial registration is not needed for this submission

eJHaemVol. 7(6)
Queen Mary University of London (GB), Cambridge University Hospitals NHS Foundation Trust (GB), University of Manchester (GB), Queen Elizabeth Hospital King's Lynn NHS Foundation Trust (GB), Addenbrooke's Hospital (GB), Blizard Institute (GB)
Platelet Disorders and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon